在这项横断面研究中，对 2016 年至 2019 年间接受子宫切除术的 211,708 名被诊断为子宫脱垂的患者进行了检查，这些患者是在医疗费用和利用项目的全国门诊手术样本中确定的，其中 2,398 名 (1.1%) 患者报告了妇科恶性肿瘤的合并诊断，并且她们在子宫切除术中接受重建手术的可能性较小（比值比 [OR] 0.90，95% CI 0.84-0.96）。这种缺乏重建手术的情况在患有完全子宫脱垂和妇科恶性肿瘤的患者中最为明显（OR 0.68，95% CI 0.57-0.81）。这种关联在共存的妇科癌前病变中也一致（n=3,357 [1.6%]）。总之，这项国家级评估表明，子宫脱垂并合并妇科恶性肿瘤或癌前病变的患者在子宫切除术中接受盆底功能障碍重建手术的可能性较小。版权所有 © 2023 美国妇产科学院。由 Wolters Kluwer Health, Inc. 出版。保留所有权利。

In this cross-sectional study examining 211,708 patients with a diagnosis of uterine prolapse who underwent hysterectomy between 2016 and 2019 identified in the Healthcare Cost and Utilization Project's Nationwide Ambulatory Surgery Sample, co-diagnosis of gynecologic malignancy was reported in 2,398 (1.1%) patients, and they were less likely to receive reconstructive surgery at hysterectomy (odds ratio [OR] 0.90, 95% CI 0.84-0.96). This absence of reconstructive surgery was most pronounced among patients with complete uterine prolapse and gynecologic malignancy (OR 0.68, 95% CI 0.57-0.81). The association was also consistent in coexisting gynecologic premalignancy (n=3,357 [1.6%]). In conclusion, this national-level assessment suggests that patients with uterine prolapse and coexisting gynecologic malignancy or premalignancy may be less likely to receive reconstructive surgery for pelvic floor dysfunction at hysterectomy.Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.